Importance: Pterygium is a very common disease in Australia but the statistical data on the provision of pterygium surgical services is poorly understood.
INTRODUCTION
Pterygium removal in Australia is billed to the Medicare system with a Medical Benefits Schedule (MBS) item number 42686. 1 The best practice standard for pterygium removal now involves additional surgery with an auto-conjunctival graft (MBS 42641). 2, 3 When 42686 is the only billed item number, and accepting the possibility of billing errors, then either the pterygium was removed without any conjunctival autograft which is likely to result in very high recurrence rates 2 or the pterygium removal was undertaken in conjunction with adjuvants such as mitomycin or radiotherapy. We do not have direct data to support the percentage of any of these other methods being used. Understanding the trend in the use of a conjunctival autograft may allow us to predict the likelihood of pterygium recurrence and indirectly the likelihood of complications from the use of adjunctive agents such as radiotherapy and mitomycin.
Ophthalmologists operating on patients for other reasons, such as cataract removal (MBS 42702) may use the opportunity to removal a concurrent pterygium which may be present in many of the cataract patients. 4 Any other procedure in the item range MBS 42503 to 42872 may also be undertaken simultaneously with a pterygium removal.
We have monitored 8 years of Department of Human Services (Medicare) summary data at national and state level to describe patterns in the use of ocular surgery MBS item numbers. Firstly, we considered whether there has been variation in proportions of patients receiving a simultaneous auto-conjunctival graft procedure. We expected to demonstrate an overall rise in its uptake, and explored this by state-specific variation in this trend.
Secondly, in patients where another procedure other than an auto-conjunctival graft, was performed simultaneously with a pterygium removal, we describe the variety of surgical procedures which have been associated with pterygium removal and their variation over the 8-year period.
METHODS Data
An annual request, consistently structured, was made by one author (Lawrence Hirst) to the Australian Government Department of Human Services, Strategic Information Design and Governance Branch, to provide the following summary data about pterygium removal services rendered in the financial years spanning 1 July 2005 to 30 June 2013. Data were supplied at national and state-specific Australian Capital Territory-New South Wales (ACT-NSW), Queensland (QLD), South Australia-Northern Territory (SA-NT), Victoria-Tasmania (VIC-TAS), Western Australia (WA) levels for: . Hence, for these years, the number of services for our purposes were derived with back-transformation by multiplying the number of providers by corresponding mean services (mean only used to revert to the original true counts). We were not aiming to describe averages.
Data were provided annually. From year 2008-2009, the presentation format provided directly the numbers of services. For the preceding years, we had to derive numbers of services from summary statistics: multiplying number of providers by the MBS item mean.
Where counts of services rendered were for one MBS item concurrently with another, their format presented as duplicate lines of information for all but the leading item numbers. Occasionally, the numbers of services mismatched by one or two, and we chose the greater since the services were rendered.
Patterns for the subgroups were based on describing a minimum of five services per group to retain our analytical confidence.
Data analysis
This is a descriptive study. For the first aim, we calculated the percentage of total pterygium removal procedures (MBS 42686) undertaken in conjunction with auto-conjunctival grafts (MBS 42641). National and state-specific summaries are presented in line graphs.
To address the second aim at both national and state levels, we tabulated the frequency of each procedure mentioned in the base year of 2005, in rank order of descending frequency (excluding autoconjunctival graft MBS 42641). To avoid potential identification of individual clinicians, and also in the spirit of descriptive qualitative research, we do not specify frequencies precisely when the frequency was less than 20.
All item numbers are listed here. However, we restricted ourselves to the highest ranked top three concurrent procedures in order that we report meaningful clinically relevant data at national and state, whilst retaining de-identified state-specific level commentary,
RESULTS

Frequency of pterygium removals
In the base year of 1 July 2005 to 30 June 2006, a total of 6662 pterygium removals were undertaken nationally; 34% in ACT-NSW, 30% in QLD, 6% in SA-NT, 20% in Vic-Tas and 10% in WA.
In terms of absolute numbers of procedures performed, pterygium removal services steadily increased to 2009/2010 (7356), thereafter steadily decreasing in the time frame studied (6492 by 2012/2013). Year-specific distributions were similar to that noted above, varying between 1.1% and 3.5% (absolute). There was no pattern to the variability over the years (data not shown).
Pterygium removals rendered concurrently with auto-conjunctival grafts
The majority of pterygium removal procedures were performed in tandem with an auto-conjunctival graft. In 2005/2006, 73% were done so nationally. There was a substantial increase of 6% in the following year, and steady increases thereafter until a plateau in 2010/2011 at about 88%.
The overall national percentage quoted for 2005/2006 ranged from 54% to 94% depending on the state (Fig. 1) . Victoria/Tasmania used this approach least and Western Australia the most. The remaining states ranged from 70% to 81%. Western Australia did not alter its pattern of rendering 42686 + 42641 procedures over the time interval in this study. In all other states, there was an increased uptake of this paired procedure over the 8 years of the study. Of particular note is the steep slope of the Victoria/Tasmania trend and how, by June 2013, it had achieved alignment with all other states in terms of uptake of the 42686 + 42641 procedure. 
Pterygium removals with other procedures
Other services
Between 33 and 43 other services were listed as being performed simultaneously with pterygium removal. Five common procedures were always in the top of these 43 services. 
DISCUSSION
Pterygium in Australia is a very common condition with prevalence rates ranging from 2%-10%. 4, 5 It might be reasonably deduced that more than 750 000 Australians may have a pterygium present on an eye.
Most patients with a pterygium either, have no symptoms, or other requirements for surgery, as evidenced by fewer than 7000 pterygium removals each year. In a Medicare study performed in 2001, it was noted that approximately 45% were combined with a conjunctival autograft. 6 As MBS 42641, auto-conjunctival graft, is the only separate item number of a procedure that has been shown to be effective 3 in the treatment of a pterygium to prevent recurrence, it is possible to identify the rate of uptake of this procedure in treating pterygium. Nine years after this study 6 the rate of use of conjunctival autografts had risen to 88% of surgeries for pterygium. Surgery in Australia which confirms the place of autoconjunctival graft as the 'Gold Standard' for pterygium removal. However, this leaves 12% of patients undergoing strictly an excision of the pterygium alone which has an unacceptable recurrence rate of up to 80%. 2 It is likely that an adjunctive treatment such as mitomycin or radiotherapy is being added to this type of removal to reduce the recurrence rate but this cannot be determined by this study. As previously shown, the rate of radiotherapy for pterygium in Queensland at least, 7 has fallen to almost zero and it is likely that with the knowledge of the long-term complications associated with radiotherapy 8 being more widely recognized, that other states may have followed suit. This means that most likely either the commonly used adjuvant of mitomycin is being used, or no additional technique other than excision of the pterygium is undertaken in 12% of pterygium removals in Australia, excluding the possibility of billing errors. It would be imperative that the surgeons who continue to use mitomycin advise their patients of the real potential of vision threatening complications that mitomycin can bring and which may take 10-15 years to evolve, 3, 9 or if no adjunctive agents are used, that patients are informed that the recurrence rate may be as high as 80%. 2 In either case, the patient is not well served by being treated with a potentially dangerous adjunctive agent such as mitomycin, or by the high risk of recurrence following simple excision.
With respect to simultaneous surgery with a pterygium removal it would be worthwhile addressing each of these concurrent surgeries separately.
42638 CONJUNCTIVAL GRAFT OVER CORNEA. It is hard to explain when conjunctiva should be pulled over onto the cornea if this is an adjunctive procedure to prevent pterygium recurrence. This will result in conjunctiva adhering to the peripheral cornea resulting in an appearance which would be unsightly or even worse be construed by the patient as a recurrence of the pterygium. There are no reported series of pterygium removals where the conjunctiva is intentionally pulled across the cornea. Perhaps this code may have been used in error by the surgeon.
42702 LENS EXTRACTION AND INSERTION OF INTRAOCULAR LENS. Although a pterygium could be technically removed at the time of cataract surgery, this would generally not be considered appropriate as the removal of the pterygium may change the corneal curvature so that the implanted IOL may no longer have the most appropriate power. 10, 11 As well, it seems extremely likely that, as an auto-conjunctival graft has not been used in these patients, that the removal of the pterygium was simply an excision with no other adjunctive agents used to reduce the recurrence rate from the unacceptable rate that may be as high as 80%. 2 It is conceivable that the surgeons may have used mitomycin to reduce the recurrence rate but in this case the simultaneous use of mitomycin with intraocular surgery would be considered potentially dangerous.
42689 PINGUECULA, removal. It is highly likely that if a pinguecula is present as it is in nearly 70% of Australians, 12 that it would have been removed at the same time as the pterygium so it is difficult to explain the use of an additional MBS item number. 42632 EYE, PENETRATING WOUND OR RUPTURE OF, not involving intraocular structures repair involving suture of cornea or sclera, or both, not being a service to which item 42632 applies. It is virtually impossible to explain why a surgeon would be removing a pterygium at the same time as repairing a penetrating wound of the eye as this would be compromising both the repair of the wound and exposing the pterygium surgery to an increased risk of infection from the external source of the wound.
42673 ADDITIONAL CORNEAL INCISIONS, to correct corneal astigmatism of more than 1 1 / 2 dioptres, including appropriate measurements and calculations, performed in conjunction with other anterior segment surgery. Once again, the removal of a pterygium with its unpredictable effect on astigmatism 10, 11 should not be performed simultaneously with corneal incisions designed to correct astigmatism.
Performing some of these surgeries concurrently, can potentially expose the patient to a worse than expected outcome of the primary surgery and the pterygium surgery. Pterygium surgery when used in conjunction with intraocular surgery may result in an increased risk of endophthalmitis.
Although our request for the use of Medicare statistics was designed to address the changing pattern of pterygium surgery, we were surprised to see the frequency with which it was linked to other surgeries which might be adversely affected by simultaneous pterygium surgery.
It is hoped that surgeons will reconsider the appropriateness of excising a pterygium concurrently with procedures other than an auto-conjunctival graft.
As well, surgeons not using an auto-conjunctival graft to reduce recurrence rates, should give serious consideration to their discussions with patients when mitomycin is the adjunctive agent to be used, in view of the potentially sight-threatening complications that may attend the use of mitomycin. 
